Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,861 INR
Change Today -39.00 / -2.05%
Volume 1.6M
LPC On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:06 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

lupin ltd (LPC) Snapshot

Open
1,925
Previous Close
1,900
Day High
1,935
Day Low
1,838
52 Week High
04/8/15 - 2,115
52 Week Low
09/1/14 - 1,280
Market Cap
837.5B
Average Volume 10 Days
1.7M
EPS TTM
53.54
Shares Outstanding
450.1M
EX-Date
07/14/15
P/E TM
34.8x
Dividend
7.50
Dividend Yield
0.40%
Current Stock Chart for LUPIN LTD (LPC)

Related News

No related news articles were found.

lupin ltd (LPC) Related Businessweek News

No Related Businessweek News Found

lupin ltd (LPC) Details

Lupin Limited, a pharmaceutical company, produces, develops, and markets a range of branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the areas of cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), gastro-intestinal, anti-diabetic, anti-infective, NSAID, anti- tuberculosis, cephalosporin, gynaecology, and other therapeutic areas; and APIs for use in therapeutic areas of antibiotics, anti-tuberculosis, cardiovascular, CNS, analgesics, and anti-gout. The company also develops drug delivery technologies; and creates and develops biosimilars for various therapeutic indications, such as oncology, inflammation, antivirals, osteoporosis, rheumatoid arthritis, and ophthalmics. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain and inflammation, infections, and metabolic/endocrine disorders. Lupin Limited has a strategic licensing agreement with InspiRX Inc. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

15,000 Employees
Last Reported Date: 06/27/15
Founded in 1968

lupin ltd (LPC) Top Compensated Officers

Founder, Chairman, Chairman of Allotment Comm...
Total Annual Compensation: 36.7M
Chief Financial Officer and Member of Risk Ma...
Total Annual Compensation: 79.2M
Vice Chairman, Chairman of Share Transfer Com...
Total Annual Compensation: 139.4M
Managing Director, Executive Director, Member...
Total Annual Compensation: 81.5M
Executive Director, Member of Share Transfer ...
Total Annual Compensation: 4.6M
Compensation as of Fiscal Year 2015.

lupin ltd (LPC) Key Developments

Lupin Limited Receives FDA Approval for Generic Prilosec Capsules

Lupin Limited announced that it has received final approval for its Omeprazole delayed-released capsules 10 mg from the FDA to market a generic version of AstraZeneca Pharmaceuticals LP Prilosec delayed-released capsules 10 mg.

Lupin Limited Receives FDA Approval for Fenofibrate Tablets, 54 Mg and 160 Mg

Lupin Limited announced that it has received final approval for its Fenofibrate Tablets 54 mg and 160 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Teva's Fenofibrate Tablets, 54 mg and 160 mg. Lupin's US subsidiary, Lupin Pharmaceuticals Inc. would commence promoting the product shortly in the US. Lupin's Fenofibrate Tablets 54 mg and 160 mg is the AB rated generic equivalent of the current reference listed drug, Fenofibrate Tablets 54 mg and 160 mg of Teva. It is indicated as an adjunct to diet to reduce elevated LDL- C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and for treatment of adult patients with severe hypertriglyceridemia.

Cipla Reportedly Mulls Acquisition Of Stake In Kremers

Cipla Limited (NSEI:CIPLA) reportedly seeking acquisition of stakes in Kremers Urban Pharmaceuticals Inc. from UCB S.A. (ENXTBR:UCB). Cipla has emerged as the sole Indian contender for Kremers Urban Pharmaceuticals Inc. which is pegged at around $1.3 billion. "Cipla is the only Indian bidder for KU but it is pitted against a few powerful private equity players. It also depends on whether Cipla is prepared to shell out a large amount in a single bid," an industry watcher told Economic Times. Lupin Limited (BSE:500257) and Torrent Pharmaceuticals Ltd. (BSE:500420) were named as the other two Indian parties that had initially shown interest but eventually opted out. One of them is China's conglomerate China Grand Group. UCB floated the divestiture of Kremers Urban in 2014. In response to questions from ET, a Cipla spokesperson said the company does not comment on any product or partner discussions. Kremers had sales of $463 million in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPC:IN 1,860.85 INR -39.00

LPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $63.15 USD +1.98
H Lundbeck A/S kr209.20 DKK -0.80
Ipca Laboratories Ltd 782.45 INR +7.40
Krka dd Novo mesto €62.30 EUR +0.50
Piramal Enterprises Ltd 932.25 INR +39.00
View Industry Companies
 

Industry Analysis

LPC

Industry Average

Valuation LPC Industry Range
Price/Earnings 35.1x
Price/Sales 6.4x
Price/Book 9.1x
Price/Cash Flow 29.5x
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUPIN LTD, please visit www.lupinworld.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.